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Two complementary approaches 
for intracellular delivery of 
exogenous enzymes
Aleksander Rust1, Hazirah H. A. Hassan1, Svetlana Sedelnikova1, Dhevahi Niranjan2, 
Guillaume Hautbergue1, Shaymaa A. Abbas1, Lynda Partridge1, David Rice1, Thomas Binz3 
& Bazbek Davletov1
Intracellular delivery of biologically active proteins remains a formidable challenge in biomedical 
research. Here we show that biomedically relevant enzymes can be delivered into cells using a new 
DNA transfection reagent, lipofectamine 3000, allowing assessment of their intracellular functions. 
We also show that the J774.2 macrophage cell line exhibits unusual intracellular uptake of structurally 
and functionally distinct enzymes providing a convenient, reagent-free approach for evaluation of 
intracellular activities of enzymes.
The cell interior is protected by cellular membranes that present an obstacle for the delivery of biolog-
ical macromolecules into the cytosol for research or therapeutic purposes1. Biologicals have become 
increasingly popular over recent years as small molecule pipelines have decreased2. Enzymes have been 
investigated for therapeutic use due to their highly specific biological activity. The selective and catalytic 
nature of these enzymes enables them to exert effects on complex cellular processes at low (nanomolar) 
concentrations not possible with most chemical drugs. The majority of current therapeutic enzymes tar-
get extracellular processes contributing to disease; for instance, asparaginases are used in the treatment 
of leukaemia to decrease serum levels of asparagine3 whilst DNases are used to break down extracellular 
DNA in the treatment of cystic fibrosis4. The identification and characterisation of intracellularly active 
enzymes with therapeutic potential has been hindered by the impermeable nature of cell membranes. 
Given the great promise enzymes offer for the development of future therapies, new tools that assist 
investigation of their function in the intracellular environment are highly desirable.
Cells can take up many macromolecules by endocytosis, but these macromolecules are normally chan-
nelled into the endolysosomal pathway resulting in their degradation5. To overcome this problem a range 
of techniques to aid the delivery of proteins into the cytosol have been developed. These include physical 
techniques, such as microinjection and electroporation, and biochemical techniques utilising protein 
transduction reagents, cell-penetrating and endosome-disrupting peptides5,6. These techniques, how-
ever, often suffer from issues of complexity, low efficiency and cytotoxicity, demanding new approaches6. 
Simple and efficient delivery of proteins into cells remains a bottleneck for assaying intracellular function, 
greatly limiting the flexibility of experimental design.
We have recently demonstrated that botulinum-derived proteases can be easily delivered into neu-
roendocrine cells using certain DNA lipofection reagents, revealing a novel action of botulinum enzyme 
type C in neuroendocrine tumour cells7. Here we investigated whether this approach could be applied to 
other biomedically relevant proteins such as translation-inhibiting enzymes. We used a range of cancer 
cell lines and show that lipofectamine 3000 efficiently delivers enzymes into the cytosol. Remarkably, a 
macrophage cell line J774.2 exhibited high sensitivity to extracellular proteins even without lipofection, 
enabling future high-throughput screening of bioactive enzymes.
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Results
The ribosome-inactivating protein saporin is a plant-derived enzyme which can potently inhibit protein 
translation and is thus widely used in biomedical research related to cancer and neurological function8,9. 
Unmodified saporin cannot enter cells but at high, micromolar concentrations it can trigger apoptosis 
due to background endocytosis. When saporin is targeted to cell membrane receptors using antibodies 
or ligands, its cytotoxic effects can be observed at therapeutically relevant, nanomolar concentrations8. 
We tested a range of transfection reagents, including lipofectamine 3000 (LF3000), lipofectamine LTX 
and proteofectene, a bona-fide protein transfection reagent, for their ability to deliver saporin into mouse 
neuroblastoma N2a cells. Cell counting using a tetrazolium salt-based assay revealed that saporin at 
30 nM concentration, in the absence of any delivery reagent, was not cytotoxic after 72 hrs when com-
pared to the untreated control (Fig.  1A). The presence of the newly-introduced LF3000 led to a dra-
matic, ten-fold drop in cell survival whilst proteofectene and lipofectamine LTX exhibited only modest 
effects (Fig. 1A). Titration experiments demonstrated that LF3000 increased the sensitivity of N2a cells 
to saporin by 1000 fold (Fig. 1B). None of the transfection reagents displayed toxicity on their own.
Next, we investigated whether efficient LF3000-based delivery of saporin can be reproduced in other 
cancer cell lines: human neuroblastoma SH-SY5Y, human lung adenocarcinoma A549 and mouse mac-
rophage J774.2 cells. The LF3000 significantly enhanced cytoxicity of saporin towards the human neu-
roblastoma and lung cancer cells. Remarkably, the J774.2 macrophage cell line was sensitive to saporin 
regardless of the presence of LF3000 (Fig.  1C). Titration experiments with the three cancer cell lines 
confirmed that J774.2 macrophage cells exhibit an unusual sensitivity to saporin compared to other cells 
(Fig. 1D).
Figure 1. Intracellular delivery of ribosome-inactivating enzyme saporin. (A) Saporin (30 nM) potently 
inhibits growth of neuroblastoma N2a cells in the presence of lipofectamine 3000 (LF3000), but not in 
the presence of lipofectamine LTX or proteofectene upon 72 hr exposure. (B) LF3000 drastically increases 
sensitivity of the neuroblastoma cells to saporin (EC50 = 1 nM with LF3000). (C) LF3000 renders the 
indicated cells sensitive to saporin (30 nM) whereas the macrophage J774.2 cell line exhibits sensitivity even 
in the absence of LF3000. (D) Saporin inhibits growth of the J774.2 cells at low nanomolar concentrations 
whereas its effect on mouse neuroblastoma N2a cells and human lung cancer A549 cells is evident only 
above 100 nM concentrations. All experiments were in triplicates, mean ± SEM.
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To assess whether J774.2 macrophages are penetrable to structurally/functionally distinct proteins, 
we analysed biological effects of the enzyme derived from botulinum neurotoxin type D. This protease 
cleaves the vesicle-associated membrane proteins (VAMPs) involved in membrane trafficking including 
VAMP3, also known as cellubrevin, which is ubiquitously present in all cells10. When the botulinum 
protease was incubated with J774.2 cells and neuroblastoma N2a cells for 72 hrs, we detected efficient 
cleavage of VAMP3 by Western immunoblotting only in the J774.2 cells (Fig. 2A). Interestingly, cleavage 
of VAMP3 resulted in a dramatic change in cell morphology with the macrophage-derived cells adopt-
ing a stellate phenotype (Fig. 2B). A similar phenomenon has been observed in previous studies where 
VAMP3 expression was knocked down using a siRNA approach implicating VAMP3 in cell spreading, 
adhesion and migration of macrophages11. Thus the J774.2 cell line may present a convenient model to 
study effects of externally applied enzymes on intracellular substrates.
Next we used J774.2 cells to compare the efficacy of four enzymes targeting translation mechanisms 
(Fig. 3A). Among these, ricin-derived enzyme and saporin both cleave the N-glycosidic bond of an ade-
nine in the 28S ribosomal RNA causing a potent block of protein translation8. Diphtheria toxin-derived 
enzyme, on the other hand, transfers ADP-ribose to a histidine of eukaryotic elongation factor 2, inhib-
iting the polypeptide elongation phase of protein synthesis12. Burkholderia lethal factor 1 (BLF1), is a 
newly discovered enzyme which acts by inhibiting the eukaryotic initiation factor 4A (eIF4A) thereby 
specifically targeting the initiation step of protein translation13. By using the J774.2 cell line, we were able 
Figure 2. The macrophage J774.2 cell line is sensitive to the botulinum enzyme type D. (A) Immunoblot 
showing cleavage of VAMP3 in J774.2, but not in N2a cells, by botulinum enzyme type D at the indicated 
concentrations after 72 hrs incubation. (B) The J774.2 cells exhibit splayed morphology after 72 hrs 
incubation in the presence of botulinum enzyme type D (100 nM).
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to bypass the need for protein delivery techniques and directly compare the effects of these four enzymes. 
Titration experiments using the cell proliferation assay showed that BLF1 had a similar inhibitory potency 
to ricin and diphtheria (EC50 ≈ 10 nM) but was five times less efficient than saporin (Fig. 3B). Analysis of 
nuclear morphology by Hoechst staining revealed that saporin, ricin and diphtheria enzymes all caused 
chromatin condensation characteristic of apoptosis, whereas BLF1 appeared to inhibit proliferation with 
minimal effects on nuclei at low nanomolar concentrations (Fig. 3C). Further analysis using a fluorescent 
caspase 3/7-based assay confirmed that saporin induces apoptosis at low nanomolar levels whereas the 
J774.2 cells survived treatment by BLF1 at a similar concentration (Fig. 3D,E).
To examine the mode of uptake of proteins by J774.2 cells, we made mCherry-tagged BLF1 con-
structs including an enzymatically inactive C94S mutant13 (Fig.  4A). Titration experiments show that 
the mCherry-fused BLF1 enzyme exhibits the same level of growth inhibition as the non-tagged version 
(Fig. 4B) The increase in size of the protein from 24 kDa to 50 kDa did not affect BLF1 action, suggesting 
that protein uptake and entry into the cytosol are size independent, at least in this protein range. The 
catalytically inactive C94S mutant did not interfere with cell growth, confirming that growth inhibition is 
Figure 3. Intracellular effects of translation-inhibiting enzymes on the macrophage J774.2 cell line. (A) 
Coomassie-stained SDS-PAGE gel showing the enzymes used (2 μ g per well). (B) Translation-inhibiting 
BLF1, ricin-derived enzyme and diphtheria toxin-derived enzyme exhibit similar efficiency (EC50 ≈ 10 nM) 
whereas saporin blocks cell growth with EC50 ≈ 2 nM. (C) Hoechst staining reveals that saporin, ricin- and 
diphtheria-derived enzymes cause chromatin condensation, whereas BLF1 has minimal effects on nuclei; all 
enzymes tested at 30 nM. (D) Representative images of the J774.2 cells stained using caspase 3/7-detecting 
reagent show apoptosis after treatment with 30 nM saporin but not 30 nM BLF1. (E) Bar chart showing that 
at similar concentrations BLF1 does not cause apoptosis as measured by the fluorescent caspase 3/7 assay. 
All experiments were in triplicates, mean ± SEM.
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due to the BLF1 enzymatic action rather than general protein uptake. Analysis by flow cytometry demon-
strated that mCherry-labelled proteins accumulated gradually inside cells and were present at detectable 
levels in almost all J774.2 cells by 24 hours, suggesting a non-specific fluid phase uptake that might be 
indicative of macropinocytosis (Fig. 4C). Macrophages are known to exhibit not only phagocytosis but 
also macropinocytosis, a form of non-selective uptake of fluid and solid cargo, which plays a major role 
in antigen presentation14. We therefore investigated the effects of amiloride, a known inhibitor of mac-
ropinocytosis, on the internalisation of the mCherry-labelled BLF1 C94S15. Pre-incubation of J774.2 cells 
with 1 mM amiloride for 30 min followed by a 4 hour incubation with mCherry-tagged protein showed 
Figure 4. Cytostatic effect of BLF1 is due to its enzymatic activity and may be associated with 
macropinocytosis in the macrophage J774.2 cell line. (A) Coomassie-stained gel showing BLF1, mCherry-
fused BLF1 and C94S inactive mutant. (B) Titration curves showing that fusing mCherry to BLF1 still 
permits cytosolic entry and activity whereas a single cysteine to serine mutation abolishes BLF1 cytostatic 
effects. (C) Bar chart showing uptake of the mCherry-BLF1 proteins at indicated times measured by flow-
cytometry. (D) Fluorescence microscopy images showing decreased uptake of mCheC94S (1 μ M) in the 
presence of 1 mM amiloride. The bar charts show a 50% reduction in uptake of mCheC94S in the presence 
of 1 mM amiloride (lower left panel) with little effect on viability (lower right panel). (E) Representative 
images showing strong colocalization of mCheC94S with FITC-dextran (70 kDa) with the cytofluorogram 
demonstrating high level of colocalization between mCheC94S and FITC-dextran (Pearson correlation 
coefficient, r = 0.91, SEM: ±0.006). (F) Flow cytometry of FITC-dextran uptake for 1 hour at 37 °C or on 
ice (0 °C) in different cell lines demonstrates the uniquely high level of dextran uptake by J774.2 cells. All 
experiments were in triplicates, mean ± SEM.
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a strong decrease in internalisation compared to the untreated control (Fig. 4D, 50%, p < 0.05). Next, we 
carried out co-localization studies with FITC-tagged dextran (70 kDa), a fluid phase marker commonly 
used in macropinocytosis studies16. Fluorescence microscopy showed almost complete co-localisation of 
mCherry-tagged C94S mutant with FITC-dextran (Fig. 4E), indicating that internalisation of C94S takes 
place via macropinocytosis. Quantification of FITC-dextran internalisation by flow-cytometry revealed 
that J774.2 cells exhibit a five times higher uptake activity compared to other tested cell lines at 37 °C 
(Fig.  4F). The enhanced macropinocytic activity of the J774.2 macrophage cell line may explain their 
acute sensitivity to externally applied enzymes.
The cytostatic nature of BLF1 observed in J774.2 cells could be important in biomedical applications. 
To confirm that the blockade of translation initiation by BLF1 can arrest cell growth without causing cell 
death, we analysed its effects on the neuroblastoma N2a cell line. As demonstrated in Fig. 1, these cells 
require LF3000 for cytosolic enzyme delivery. Incubation of the N2a cells with BLF1 in the presence of 
LF3000 for 72 hrs led to a dramatic inhibition of neuroblastoma growth at 1 nM concentration (Fig. 5A). 
Time-lapse microscopy confirmed that BLF1 significantly retards neuroblastoma cell growth with no 
apparent loss of cellular integrity (Fig.  5B and Supplementary movies). Following 24 hr incubation of 
mCherry-BLF1 with LF3000, the fluorescent protein was highly enriched in segregated dense vesicle-like 
structures near nuclei in the vast majority of the N2a cells (Fig.  5C). The observed cytostatic effects 
of BLF1 at low nanomolar concentrations indicate that LF3000 not only concentrates proteins in the 
vesicular structures but also induces leakiness of the endocytic membranes to achieve its transfection/
transduction effects.
Discussion
In this study we demonstrated that the recently-introduced lipofection reagent LF3000 allows efficient 
delivery of enzymes into a range of cancer cells. We also demonstrated that the macrophage J774.2 
cell line is uniquely penetrable to intracellularly-active enzymes. The important advantage of these two 
Figure 5. BLF1 enzyme arrests growth of neuroblastoma N2a cells. (A) Titration of BLF1 in the absence 
and presence of LF3000 indicates EC50 ≈ 1 nM for the intracellular activity of this enzyme at 72 hrs. (B) 
Representative images of the N2a tumour cells treated with LF3000 in the absence (left panel) or presence of 
30 nM BLF1 (right panel) demonstrate an arrested state with BLF1 after 68 hrs (full time-lapse microscopy is 
in Supplementary information). (C) Representative images showing enhanced uptake of mCherry-BLF1 by 
N2A cells in the presence of LF3000. Punctate vesicular staining is evident in all cells treated with LF3000. 
All experiments were in triplicates, mean ± SEM.
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methods for protein delivery is that they offer a more uniform intracellular introduction of enzymes 
compared to microinjections or DNA-based protein expression. The mechanisms underlying the advan-
tageous characteristics of LF3000 over other lipofection and proteofection reagents are currently unclear 
due to proprietary reasons. Its universal availability, nevertheless, will allow cross-referencing with other 
cells and biological macromolecules. The unique penetrability of the J774.2 cells raises important ques-
tions for future investigations. We have shown that J774.2 cells exhibit enhanced macropinocytosis, and 
indeed a recent study shows that induction of macropinocytosis can help to drive intracellular delivery 
of native proteins17. However, it would be interesting to determine how exactly the enhanced uptake via 
macropinocytosis may account for the unusual sensitivity of J774.2 cells to the cytosolic action of exter-
nally applied enzymes. We speculate that protein translocation into the cytosol of J774.2 macrophages 
occurs during cross-presentation, which can involve export of polypeptides from endocytic-like com-
partments into the cytosol for degradation. Despite intense research over decades, mechanistic details 
of how uptaken proteins are transported into the cytoplasm are still under investigation18. It will be 
interesting to determine whether primary macrophages and other macrophage cell lines have a similar 
sensitivity to exogenous proteins. Regardless of the exact nature of cytosolic entry, the two presented 
methods provide a useful platform to start addressing the intracellular action of various enzymes without 
the need for complicated protein delivery techniques such as microinjection or specialised and costly 
peptide-based approaches5,6.
Our investigation revealed that botulinum-derived enzymes can affect the biology of immune cells 
by cleaving a single protein, VAMP3. Further, we showed that among translation-inhibiting enzymes, 
saporin exhibits the highest efficacy which is, however, associated with cytotoxicity. One issue with 
saporin and other ribosome-inactivating proteins is their high potency against all cells, making precise 
targeting to tumour cells of paramount importance. Since antigens expressed solely on tumour cells are 
rare, hepatotoxicity and capillary leak syndrome are common with these forms of treatment8. By con-
trast, the recently discovered BLF1 enzyme, which targets the eIF4A initiation factor, was able to block 
cell growth with little cytotoxicity. Blocking initiation of translation has recently gained considerable 
attention19 and our data on BLF1 action may be relevant to the design of new anti-cancer therapies. In 
addition to cancer treatment, blocking initiation of translation in neurons has recently been suggested 
as a possible therapeutic route for pain relief and other neurological disorders20. Our new data on neu-
roblastoma cells makes BLF1 an interesting candidate for inhibiting protein translation in pain-related 
neurons. These findings illustrate the effectiveness of the two complementary methods for assaying intra-
cellular actions of exogenous enzymes and open new avenues for high-throughput screening and quality 
control in biotechnology.
Methods
Cell Culture. Cell lines were maintained in a 37 °C incubator at 5% CO2. The N2a (ATCC), J774.2 
(ECACC) and A549 (ECACC) cell lines were cultured in Dulbecco’s Modified Eagle Medium (Gibco) 
supplemented with 10% fetal bovine serum (FBS) (Gibco). SH-SY5Y cells (Sigma-Aldrich) were cultured 
in a 1:1 ratio of Eagle’s Minimum Essential Medium (Gibco) and F12 Medium (Gibco) supplemented 
with 1% non-essential amino acids (Gibco) and 15% FBS. HeLa cells (ECACC) were cultured in EMEM 
with 10% FBS, U937 cells (gift from Dr Jim Gallagher) were cultured in RPMI (Gibco) with 25 mM 
HEPES (Gibco) and 10% FBS, and RBL-2H3 cells (gift from Dr Birgit Helm) were cultured in DMEM 
(Gibco) with 1% non-essential amino acids and 10% FBS. Cells were plated at a density of 3 × 104 cells 
per well in uncoated 48-well plates (Corning) or at 5 × 103 cells per well in uncoated 96-well plates 
(Corning). For microscopy, 96-well plates with a μ Clear base were used (Greiner Bio-one) for better 
resolution.
Enzymes and Protein Transduction. Botulinum protease type D-encoding DNA fragment (aa 
1-446) was inserted into pQE3 (Qiagen) using EcoRI and SalI sites. Complementary oligonucleotides 
encoding the histidine affinity tag PPTPGHHHHHH followed by a stop codon were ligated into the 
EcoRV site to yield pBN31. The botulinum protease was produced in E.coli M15pREP4 strain (Qiagen) 
following 3 h of induction at 21 °C and purified on Ni2+-nitrilotriacetic acid agarose. Fractions con-
taining the botulinum protease were pooled and dialyzed against 150 mM potassium glutamate, 10 mM 
HEPES-KOH, pH 7.2, frozen in liquid nitrogen, and kept at − 70 °C. Saporin from Saponaria officinalis 
seeds was obtained from Sigma-Aldrich. BLF1 was purified as previously described13. BLF1 was cloned as 
a PCR fragment into pET14b (Novagen) using the NdeI and BamHI sites, allowing expression of N-term 
6xHis tagged BLF1. 6xHis-mCherry-tagged BLF1 was built following two successive steps: (i) BLF1 was 
first cloned as a XbaI PCR fragment into pGEX KG-mCherry construct21, (ii) mCherry-BLF1 was then 
cloned as a NdeI/BamHI PCR fragment into pET14b (Novagen). Both 6xHis and 6His-mCherry tagged 
BLF1 were expressed into E. coli BL21-RP cells following overnight induction at 20 °C with 0.4 mM 
IPTG. Recombinant proteins were purified using Ion Metal Affinity Chromatography using TALON/
Co2+ beads (Clontech) and then on Superdex 200 gel filtration column (GE Healthcare). Ricin chain 
A-encoding DNA fragment (aa 36-302 from Ricinus communis) was inserted into PGEX-KG using 
EcoRI and NcoI sites and was purified from E.coli DE3 pLys strain after 16 hr expression at 20 °C, using 
glutathione-affinity chromatography followed by thrombin elution and gel-filtration as described21. The 
pET-15b LFN-DTA plasmid (Addgene 11075), carrying DNA encoding the diphtheria toxin-derived 
www.nature.com/scientificreports/
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enzyme (aa 33-222 from Corynephage beta), was modified to remove the LFN part by digestion with NcoI 
restriction enzyme. The diphtheria enzyme was purified as described previously22. Protein concentrations 
were estimated by SDS-PAGE (12% NuPAGE, Life Technologies) and Coomassie Blue staining with 
bovine serum albumin in a serial dilution used as a standard. Enzyme transduction was performed 6 h 
after plating using Lipofectamine LTX (Invitrogen), Lipofectamine 3000 (Invitrogen) and Proteofectene 
(Biontex). Proteins were pre-incubated for 20 minutes at 20 °C in 100 μ l Optimem (Gibco) with or with-
out 2.5 μ l of the transfection reagents, with 10 μ l (for 96-well) or 30 μ l (for 48-well) being added to the 
wells. Cells were incubated at 37 °C and 5% CO2 with the indicated proteins and transfection reagents 
for 68–72 h before being assayed.
Assays for cell viability, apoptosis, VAMP3 cleavage, flow cytometry and microscopy. Cell 
numbers were analysed using the Cell Counting Kit-8 (CCK-8; Sigma-Aldrich) according to manufac-
turer’s instructions. Briefly, the CCK-8 reagent was added in a 1/10 ratio and incubated at 37 °C for 1 h. 
Absorbance was then measured at 450 nm using a FLUOstar OPTIMA plate reader (BMG Labtech). 
Readings observed in the absence of any delivery reagent were taken as 100% after normalisation to a 
blank control (cell-free medium with CCK-8 reagent). To evaluate nuclear morphology, live cells were 
stained with Hoechst 33342 (1 μ g/ml, Invitrogen) for 20 minutes at 37 °C and observed using a digi-
tal fluorescence microscope (DMIRB, Leica Microsystems). Live cellular uptake of mCherry proteins 
was visualised using the inverted fluorescence microscope. Caspase 3/7 activity was measured using the 
CellEvent Caspase 3/7 Green detection kit (Invitrogen) according to manufacturer’s instructions. Briefly, 
the CellEvent reagent was added to cells at a final concentration of 5 μ M. Cells were then incubated 
for 30 minutes at 37 °C before imaging under a fluorescence microscope. Green fluorescent nuclei were 
indicative of caspase 3/7 activation and apoptosis. Images were taken of three different fields of vision 
for each well at 40 × magnification. Cells were then counted using the ImageJ software and the number 
of apoptotic cells was given as a percentage of total cell count. For analysis by flow cytometry, cells were 
seeded at 5 × 105 in 6-well plates and incubated in medium containing 100 μ g/ml mCherry-labelled 
BLF-1 proteins for up to 24 hours. Dextran uptake was quantified by incubation with 100 μ g/ml 
FITC-dextran for 1 hour at 37 °C or on ice. After washing, cells were harvested and analysed using a 
LSRII flow cytometer (Becton Dickinson) and FlowJo software. In amiloride experiments, J774.2 cells 
were allowed to attach for 24 hours in 96-well μ Clear plates. Cells were pre-treated for 30 minutes with 
1 mM amiloride (Sigma-Aldrich) before 4 hour incubation with 1 μ M mCheC94S. For quantification, five 
images were taken at 60 × magnification followed by analysis of cytoplasm fluorescence intensity using 
ImageJ. For dextran colocalisation studies, cells were incubated with 1 μ M mCherry-C94S and 1 μ M 
FITC-Dextran for 4 hours before fluorescence microscopy and analysis using ImageJ with the JACoP 
Plugin23. Western Immunoblotting using anti-VAMP3 antibody (gift from Andrew Peden) was carried 
out as described previously7. Time-lapse live imaging was carried out using the JuLI FL live cell movie 
analyser (NanoEnTek). After application of proteins, cells were imaged every 20 minutes for 68 h at 37 °C.
Supplementary movies. 68 hrs time lapse videos of the N2a tumour cells treated with LF3000 in 
the absence (Movie 1) or presence of 30 nM BLF1 (Movie 2) were taken to demonstrate growth arrest 
only with BLF1.
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